Your browser doesn't support javascript.
loading
Multimodal evaluation of drug antibacterial activity reveals cinnamaldehyde analog anti-biofilm effects against Haemophilus influenzae.
Asensio-López, Javier; Lázaro-Díez, María; Hernández-Cruz, Tania M; Blanco-Cabra, Núria; Sorzabal-Bellido, Ioritz; Arroyo-Urea, Eva M; Buetas, Elena; González-Paredes, Ana; Ortiz de Solórzano, Carlos; Burgui, Saioa; Torrents, Eduard; Monteserín, María; Garmendia, Junkal.
Afiliación
  • Asensio-López J; Centro de Ingeniería de Superficies y Materiales Avanzados, Asociación de la Industria Navarra (AIN), Cordovilla, Spain.
  • Lázaro-Díez M; Instituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas (IdAB-CSIC)-Gobierno de Navarra, Mutilva, Spain.
  • Hernández-Cruz TM; Instituto de Agrobiotecnología, Consejo Superior de Investigaciones Científicas (IdAB-CSIC)-Gobierno de Navarra, Mutilva, Spain.
  • Blanco-Cabra N; Centro de Ingeniería de Superficies y Materiales Avanzados, Asociación de la Industria Navarra (AIN), Cordovilla, Spain.
  • Sorzabal-Bellido I; Bacterial Infections and Antimicrobial Therapies Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
  • Arroyo-Urea EM; Microbiology Section, Department of Genetics, Microbiology, and Statistics, Biology Faculty, Universitat de Barcelona, Barcelona, Spain.
  • Buetas E; Laboratory of Microphysiological Systems and Quantitative Biology, Biomedical Engineering Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.
  • González-Paredes A; Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Madrid, Spain.
  • Ortiz de Solórzano C; Conexión Nanomedicina, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
  • Burgui S; Department of Health and Genomics, Center for Advanced Research in Public Health, FISABIO Foundation, Valencia, Spain.
  • Torrents E; Instituto de Química Médica, Consejo Superior de Investigaciones Científicas (IQM-CSIC), Madrid, Spain.
  • Monteserín M; Conexión Nanomedicina, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
  • Garmendia J; Laboratory of Microphysiological Systems and Quantitative Biology, Biomedical Engineering Program, Center for Applied Medical Research (CIMA), Pamplona, Spain.
Biofilm ; 7: 100178, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38317668
ABSTRACT
Biofilm formation by the pathobiont Haemophilus influenzae is associated with human nasopharynx colonization, otitis media in children, and chronic respiratory infections in adults suffering from chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD). ß-lactam and quinolone antibiotics are commonly used to treat these infections. However, considering the resistance of biofilm-resident bacteria to antibiotic-mediated killing, the use of antibiotics may be insufficient and require being replaced or complemented with novel strategies. Moreover, unlike the standard minimal inhibitory concentration assay used to assess antibacterial activity against planktonic cells, standardization of methods to evaluate anti-biofilm drug activity is limited. In this work, we detail a panel of protocols for systematic analysis of drug antimicrobial effect on bacterial biofilms, customized to evaluate drug effects against H. influenzae biofilms. Testing of two cinnamaldehyde analogs, (E)-trans-2-nonenal and (E)-3-decen-2-one, demonstrated their effectiveness in both H. influenzae inhibition of biofilm formation and eradication or preformed biofilms. Assay complementarity allowed quantifying the dynamics and extent of the inhibitory effects, also observed for ampicillin resistant clinical strains forming biofilms refractory to this antibiotic. Moreover, cinnamaldehyde analog encapsulation into poly(lactic-co-glycolic acid) (PLGA) polymeric nanoparticles allowed drug vehiculization while maintaining efficacy. Overall, we demonstrate the usefulness of cinnamaldehyde analogs against H. influenzae biofilms, present a test panel that can be easily adapted to a wide range of pathogens and drugs, and highlight the benefits of drug nanoencapsulation towards safe controlled release.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Biofilm Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Biofilm Año: 2024 Tipo del documento: Article País de afiliación: España Pais de publicación: Países Bajos